Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis

@inproceedings{Koutruba2010ReviewOU,
  title={Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis},
  author={Nora Koutruba and Jason Emer and Mark G. Lebwohl},
  booktitle={Therapeutics and clinical risk management},
  year={2010}
}
The pathogenesis of psoriasis is unknown, although it is generally accepted that this chronic inflammatory skin disorder is a complex autoimmune condition similar to other T-cell mediated disorders. Psoriasis imposes a heavy burden on the lifestyle of those affected due to the psychological, arthritic, and cutaneous morbidities; thus significant research has focused on the genetic and immunologic features of psoriasis in anticipation of more targeted, efficacious, and safe therapies. Recently… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

The Future of Atopic Dermatitis Treatment.

Advances in experimental medicine and biology • 2017

References

Publications referenced by this paper.
Showing 1-10 of 67 references

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

Expert review of neurotherapeutics • 2009
View 4 Excerpts
Highly Influenced

A Phase 3, Multicenter, Randomized Study Comparing Ustekinumab and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

CEM Griffiths, B Strober, R Fidelus-Gort, A. Menter
2009
View 2 Excerpts

Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease

S. Brand
A Phase 3 , Multicenter , Randomized Study Comparing Ustekinumab and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis • 2009
View 1 Excerpt

Similar Papers

Loading similar papers…